Skip to main content
Clinical Trials/ITMCTR1900002641
ITMCTR1900002641
Recruiting
未知

A multi-center, randomized controlled clinical study for Xiansen Decoction combined with radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 to 75 years, male or non\-pregnant, lactating female;
  • 2\. Histopathology is moderately differentiated or undifferentiated locally advanced nasopharyngeal carcinoma (WHO classification II\-III stage).
  • 3\. Patients with clinical T3\-4N1M0/TxN2\-3M0 (version 8 UICC/AJCC staging) who have never received radiotherapy or cytotoxic chemotherapy (single drug or combination, except induction chemotherapy) and immunotherapy.
  • 4\. ECOG:0\-1;
  • 5\. Adequate bone marrow function, hematological examination: white blood cell count \>\= 4 x 10^12/ L; neutrophil count \>\= 1\.5 x 10^12 / L; platelet count \>\= 100 x 10^9 / L; hemoglobin \>\= 9g / L;
  • 6\. Blood biochemical examination: normal liver function (or total bilirubin, AST, ALT \<\= 2\.5 times normal value upper limit), normal renal function (or creatinine clearance rate \>\= 60ml/min1\.5 normal value upper limit);
  • 7\. The subjects volunteered to join the study and signed an informed consent form with good compliance and follow\-up.

Exclusion Criteria

  • 1\. Received radiotherapy, chemotherapy or other antineoplastic therapy before the start of the clinical trial; (except induction chemotherapy).
  • 2\. Those who have or are suffering from other tumors whose primary location or histology are different from those evaluated in this study. Excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder surface tumor \[Ta,Tis\&T1], or any cured tumors enrolled in any distance for more than 3 years.
  • 3\. Patients who have or are suffering from serious oral or salivary gland diseases.
  • 4\. Patients are unwilling to stop smoking, drinking and chewing betel nuts and other bad living habits.
  • 5\. The patient has other uncontrolled serious diseases at the same time.
  • 6\. Abnormal function of heart, brain, lung and other important organs.
  • 7\. Patients who are unable to complete concurrent chemoradiotherapy or delayed treatment for more than 1 week due to subjective factors.
  • 8\. The researchers believe that there are any other situations that are not suitable for inclusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials